Shih-Meng Tsai1, Szu-Hsien Wu2,3, Ming-Feng Hou4, Hlio-Han Yang5, Li-Yu Tsai5. 1. Department of Public Health and Environmental Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 2. Division of Plastic and Reconstructive Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan. 3. Department of Surgery, School of Medicine, National Yang Ming University. 4. Cancer Center, Department of Surgery, School of Medicine, College of Medicine, Kaohsiung Medical University and Hospital, Kaohsiung, Taiwan. 5. Department of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan.
Abstract
BACKGROUND: VTCN1, a T-cell regulator, belongs to the immunoglobulin superfamily. It is more highly expressed in tumor tissues than in normal tissues, which suggests that it could serve as a tumor-related agent. We hypothesize the gene variants for this coinhibitory molecule may be associated with the risk of breast cancer, given such gene polymorphisms could affect its related gene expression. METHODS: Genotypes of the VTCN1 gene variants (rs10754339, rs10801935, and rs3738414) were analyzed in 566 patients with breast cancer and 400 age-frequency-matched controls. RESULTS: Compared with the major allele, the minor alleles of rs10754339, rs10801935, and rs3738414 did modulate the risk of breast cancer with ORs (95% CI) of 1.42 (1.07-1.89), 1.39 (1.10-1.77), and 0.81 (0.67-0.99), respectively. Those with the rs10754339 genotype AG and rs10801935 AC genotype had significantly increased risks when compared with their major genotypes. However, in rs3738414, the AA genotype had a marginally significant decreased risk compared with its wild genotype. In the haplotype-based analysis, the GCG allele was associated with significantly increased risk (OR: 1.56, 95% CI: 1.09-2.22) based on the AAG reference. Further analyses of the haplotype pairs showed GCG carriers had a significantly increased risk. CONCLUSIONS: In this study, the VTCN1 genetic variants (rs10754339, rs10801935, and rs3738414) indicate they could be connected with the risk of breast cancer, which in turn provides indirect evidence that T-cell immunity could be involved in the development of breast cancer.
BACKGROUND:VTCN1, a T-cell regulator, belongs to the immunoglobulin superfamily. It is more highly expressed in tumor tissues than in normal tissues, which suggests that it could serve as a tumor-related agent. We hypothesize the gene variants for this coinhibitory molecule may be associated with the risk of breast cancer, given such gene polymorphisms could affect its related gene expression. METHODS: Genotypes of the VTCN1 gene variants (rs10754339, rs10801935, and rs3738414) were analyzed in 566 patients with breast cancer and 400 age-frequency-matched controls. RESULTS: Compared with the major allele, the minor alleles of rs10754339, rs10801935, and rs3738414 did modulate the risk of breast cancer with ORs (95% CI) of 1.42 (1.07-1.89), 1.39 (1.10-1.77), and 0.81 (0.67-0.99), respectively. Those with the rs10754339 genotype AG and rs10801935 AC genotype had significantly increased risks when compared with their major genotypes. However, in rs3738414, the AA genotype had a marginally significant decreased risk compared with its wild genotype. In the haplotype-based analysis, the GCG allele was associated with significantly increased risk (OR: 1.56, 95% CI: 1.09-2.22) based on the AAG reference. Further analyses of the haplotype pairs showed GCG carriers had a significantly increased risk. CONCLUSIONS: In this study, the VTCN1 genetic variants (rs10754339, rs10801935, and rs3738414) indicate they could be connected with the risk of breast cancer, which in turn provides indirect evidence that T-cell immunity could be involved in the development of breast cancer.
Authors: In-Hak Choi; Gefeng Zhu; Gabriel L Sica; Scott E Strome; John C Cheville; Julie S Lau; Yuwen Zhu; Dallas B Flies; Koji Tamada; Lieping Chen Journal: J Immunol Date: 2003-11-01 Impact factor: 5.422
Authors: A I Chapoval; J Ni; J S Lau; R A Wilcox; D B Flies; D Liu; H Dong; G L Sica; G Zhu; K Tamada; L Chen Journal: Nat Immunol Date: 2001-03 Impact factor: 25.606
Authors: Barbara Tringler; Shaoqiu Zhuo; Glenn Pilkington; Kathleen C Torkko; Meenakshi Singh; M Scott Lucia; David E Heinz; Jackie Papkoff; Kenneth R Shroyer Journal: Clin Cancer Res Date: 2005-03-01 Impact factor: 12.531
Authors: Gabriel L Sica; In Hak Choi; Gefeng Zhu; Koji Tamada; Sheng Dian Wang; Hideto Tamura; Andrei I Chapoval; Dallas B Flies; Jürgen Bajorath; Lieping Chen Journal: Immunity Date: 2003-06 Impact factor: 31.745
Authors: Diana E Ramirez-Ardila; Kirsten Ruigrok-Ritstier; Jean C Helmijr; Maxime P Look; Steven van Laere; Luc Dirix; Els M J J Berns; Maurice P H M Jansen Journal: Mol Oncol Date: 2016-07-25 Impact factor: 6.603